Poseida Therapeutics, Inc. (PSTX) [Rocket]

Overview

Poseida Therapeutics, Inc. (PSTX)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/10/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/14/2023	SC 13D	Astellas US LLC reports a 8.7% stake in POSEIDA THERAPEUTICS, INC.
08/11/2023	D	Form D - Notice of Exempt Offering of Securities:
08/08/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/08/2023	8-K	Quarterly results
08/07/2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
06/16/2023	4	Collins Cynthia (Director) has filed a Form 4 on Poseida Therapeutics, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
Revenues	130.5	130.5	31.2	31.2	0.0	0.0	30.9	3.0
Revenue growth	317.7%	317.7%				-100.0%	934.6%	-69.4%
Cost of goods sold	0.0	190.4	0.0	172.6	0.0	0.0	42.0	22.7
Gross profit	130.5	-59.9	31.2	-141.4	0.0	0.0	-11.1	-19.7
Gross margin	100.0%	-45.9%	100.0%	-452.7%			-36.0%	-658.9%
Selling, general and administrative	190.4		172.6
Research and development					103.5	60.4
General and administrative		37.5		35.9	23.0	18.5	9.7	5.5
EBIT	-59.9	-59.9	-141.4	-141.4	-126.5	-85.5	-42.0	-19.7
EBIT margin	-45.9%	-45.9%	-452.7%	-452.7%			-136.0%	-658.9%
Pre-tax income	-63.5	-63.5	-125.0	-125.0	-129.8	-86.5	-44.6	-20.2
Income taxes	0.5	0.5	0.0	0.0	0.0	0.0	-0.2	0.5
Tax rate			0.0%	0.0%	0.0%	0.0%	0.5%
Net income	-64.0	-64.0	-125.0	-125.0	-129.8	-86.5	-44.4	0.0
Net margin	-49.0%	-49.0%	-400.1%	-400.1%			-143.8%	0.0%

Diluted EPS	($0.89)	($0.89)	($2.01)	($2.01)	($3.61)	($6.86)	($3.64)
Shares outstanding (diluted)	72.0	72.0	62.2	62.2	36.0	12.6	12.2

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.